LLY

757.36

+3.2%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

LLY

757.36

+3.2%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

LLY

757.36

+3.2%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

LLY

757.36

+3.2%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

LLY

757.36

+3.2%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

ABT

134.76

+1.17%↑

Search

Johnson and Johnson

Geschlossen

BrancheGesundheitswesen

151.29 1.18

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

149.01

Max

151.45

Schlüsselkennzahlen

By Trading Economics

Einkommen

7.6B

11B

Verkäufe

-627M

22B

KGV

Branchendurchschnitt

17.146

56.602

EPS

2.77

Dividendenrendite

3.37

Gewinnspanne

50.24

Angestellte

138,100

EBITDA

9.7B

16B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+13.29% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

3.37%

2.45%

Nächstes Ergebnis

16. Juli 2025

Nächste Dividendenausschüttung

10. Juni 2025

Nächstes Ex-Dividendendatum

27. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-6.3B

371B

Vorheriger Eröffnungskurs

150.11

Vorheriger Schlusskurs

151.29

Nachrichtenstimmung

By Acuity

28%

72%

69 / 382 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Johnson and Johnson Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

9. Mai 2025, 17:03 UTC

Ergebnisse
Wichtige Markttreiber

Anika Therapeutics Shares Fall After Slump in 1Q Pain-Treatment Sales in U.S.

15. Apr. 2025, 15:12 UTC

Ergebnisse

J&J Boosts Outlook Despite Incoming Tariff Costs -- Update

15. Apr. 2025, 10:35 UTC

Top News
Ergebnisse

J&J Increases Outlook After Beating 1Q Expectations

12. Mai 2025, 22:14 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12. Mai 2025, 18:45 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12. Mai 2025, 17:14 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

7. Mai 2025, 09:30 UTC

Top News

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

4. Mai 2025, 04:05 UTC

Akquisitionen, Fusionen, Übernahmen

UnitedHealth's Stock Is Ailing. A Bigger Business Hasn't Helped. -- Barrons.com

18. Apr. 2025, 11:00 UTC

Top News

Johnson & Johnson Pivots Its AI Strategy -- WSJ

17. Apr. 2025, 20:34 UTC

Ergebnisse

UnitedHealth Woes Aren't Dragging Down the Entire Sector. Here's Why. -- Barrons.com

17. Apr. 2025, 18:24 UTC

Ergebnisse

UnitedHealth Woes Aren't Dragging Down the Entire Sector. Here's Why. -- Barrons.com

15. Apr. 2025, 19:06 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Bank of America, Citigroup, Netflix, Boeing, Tesla, HPE, Applied Digital, and More -- Barrons.com

15. Apr. 2025, 18:52 UTC

Market Talk
Ergebnisse

J&J's 1Q Performance Signals Positive Outlook for MedTech Sector -- Market Talk

15. Apr. 2025, 14:54 UTC

Ergebnisse

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

15. Apr. 2025, 13:19 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

15. Apr. 2025, 11:52 UTC

Ergebnisse

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Slips. -- Barrons.com

15. Apr. 2025, 11:14 UTC

Ergebnisse

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Slips. -- Barrons.com

15. Apr. 2025, 10:51 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Boeing, Tesla, Bank of America, J&J, Netflix, Allegro MicroSystems, and More -- Barrons.com

15. Apr. 2025, 10:37 UTC

Top News
Ergebnisse

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Rises. -- Barrons.com

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson Now Sees 2025 Operational Sales of $91.6B-$92.4B Vs. Prior Outlook $90.9B-$91.7B >JNJ

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson Backs 2025 Adj EPS $10.50-Adj EPS $10.70 >JNJ

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson Raises 2025 View To Sales $91B-$91.8B Vs Prior View $89.2B-$90B >JNJ

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson Now Sees 2025 Adjusted Operational EPS $10.50-$10.70 Vs Prior View $10.75-$10.95 >JNJ

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson: Including Tariff Costs, Dilution From Intra-Cellular Therapies Buy and Updated Forex, Maintain FY Adj EPS Outlook of 6.2% Growth at Mid-Point >JNJ

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson: Strong 1Q Operational Sales Growth Reinforces Our Confidence in 2025 Guidance >JNJ

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 1Q Sales $21.89B >JNJ

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson: Increasing FY25 Operational Sales Guidance to Reflect Addition of Caplyta Following Completion of Intra-Cellular Therapies Acquisition >JNJ

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 1Q Worldwide MedTech Sales $8.02B >JNJ

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 1Q International Sales $9.59B >JNJ

15. Apr. 2025, 10:20 UTC

Ergebnisse

Johnson & Johnson 1Q Adj EPS $2.77 >JNJ

Peer-Vergleich

Kursveränderung

Johnson and Johnson Prognose

Kursziel

By TipRanks

13.29% Vorteil

12-Monats-Prognose

Durchschnitt 169.5 USD  13.29%

Hoch 185 USD

Tief 153 USD

Basierend auf 15 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Johnson and Johnson – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

15 ratings

7

Buy

8

Halten

0

Sell

Technischer Score

By Trading Central

154.93 / 155.895Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

69 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.